0000905148-24-003287.txt : 20241127 0000905148-24-003287.hdr.sgml : 20241127 20241127180401 ACCESSION NUMBER: 0000905148-24-003287 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20241127 DATE AS OF CHANGE: 20241127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blume-Jensen Peter CENTRAL INDEX KEY: 0001950499 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41551 FILM NUMBER: 241512720 MAIL ADDRESS: STREET 1: C/O ACRIVON THERAPEUTICS, INC. STREET 2: 480 ARSENAL WAY, SUITE 100 CITY: WATERTOWN STATE: MA ZIP: 02472 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Masson Kristina CENTRAL INDEX KEY: 0001950501 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41551 FILM NUMBER: 241512719 MAIL ADDRESS: STREET 1: C/O ACRIVON THERAPEUTICS, INC. STREET 2: 480 ARSENAL WAY, SUITE 100 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Acrivon Therapeutics, Inc. CENTRAL INDEX KEY: 0001781174 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825125532 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 ARSENAL WAY, SUITE 100 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-207-8979 MAIL ADDRESS: STREET 1: 480 ARSENAL WAY, SUITE 100 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 form4.xml X0508 4 2024-03-01 0001781174 Acrivon Therapeutics, Inc. ACRV 0001950499 Blume-Jensen Peter C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 true true President and CEO 0001950501 Masson Kristina C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 true true EVP - Business Operations false Stock Option (Right to Buy) 5.7 2024-03-01 4 A 0 225226 0 A 2034-02-28 Common Stock 225226 225226 D Stock Option (Right to Buy) 5.7 2024-03-01 4 A 0 90090 0 A 2034-02-28 Common Stock 90090 90090 I See Footnote Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact for Peter Blume-Jensen 2024-11-27 /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact for Kristina Masson 2024-11-27